Loading
Valneva SE Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 04 Nov 2025.
Valneva SE: what insiders have been doing
This page follows insider dealings at Valneva SE as filed with AMF, a company from the Healthcare & Pharma sector based in Saint-Herblain, France. The group dates from 1999. Between 18 October 2025 and 18 October 2026, 6 insiders published 16 filings.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €15k) and 6 sales (4 insiders, €213k). The net balance comes to €198k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €52k, sold by Juan Carlos JARAMILLO and made public on 26 January 2026. Those buying include 1 board member.
The latest purchase dates back some time: it was published 347 days ago, on 4 November 2025. The median gap between a trade and its publication by AMF is 3 days. The regulation allows three business days to notify a trade (MAR article 19). Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 16 filings here. Since 2021, the database holds 18 purchases and 35 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Insider Decl.
78
Thresholds
n/a
Buy Volume
€5M
18 ops. · all time
Sell Volume
€21M
35 ops. · all time
Who traded when
BuySaleAnne-Marie GRAFFIN2 buys
Juan Carlos JARAMILLO2 sales
Vincent DEQUENNE2 sales
James CONNOLLY1 buy
Peter BÜHLER1 sale
Thomas Lingelbach1 sale
Analyst consensus: bullish or bearish?
Analysts rate Valneva SE Buy (bullish), based on 7 analysts. Average price target: €6.19.
Fundamental score
Ranked 22,868 of 24,161 companies
16.3
score / 100
Value12
Quality21
FCF yld-12%
Earn yld-24%
EV/EBITDA·
ROE-118%
Gross mgn39%
Net mgn-66%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€2.53
Analyst consensus
7 analystsBuy
€2.15Target €6.19(+144%)€12.00
Income statement
Revenue€174.7M
Gross profit€67.5M39% margin
EBITDA-€50.5M-29% margin
Net income-€115.2M-110.3% margin
Valuation
PER (forward)16.4x
P/Book5.9x
Beta1.26
Balance sheet & cash
Market cap€480.4M
Total debt€207.2M
Free Cash Flow-€57.4M
Debt / Equity259%
Profitability & ownership
ROE-117.8%
ROA-16.7%
% insiders10.7%
% institutions22.7%
Last declaration on 26 January 2026
Declarations78 total
11,800 shares@ €4.407516.2% of flowActionEuronext ParisISIN FR00040568512026DD1090816
11,800 shares@ €4.3879100.0% of flowActionEuronext ParisISIN FR00040568512026DD1090814
6,206 shares@ €4.37617.5% of flowActionEuronext ParisISIN FR00040568512026DD1089349
43,455 shares@ €2.6273.2% of flowOption d'achatHors plateforme de négociationISIN FR00040568512026DD1089344
82,899 shares@ €2.6267.7% of flowOption d'achatHors plateforme de négociationISIN FR00040568512026DD1089345
13,206 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1075101
7,038 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1075103
23,622 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1075105
55,246 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1075106
23,622 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1075108
23,622 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1075099
11,310 shares@ €2.620.4% of flowOption d'achatHors plateforme de négociationISIN FR00040568512025DD1072994
3,750 shares@ €3.980522.3% of flowActionEuronext ParisISIN FR00040568512025DD1067115
Canonical exit: 1 Feb 2026 (T+90)
3,239 shares@ €4.46849.3% of flowActionEuronext ParisISIN FR00040568512025DD1064405
9,867 shares@ €4.4684100.0% of flowActionEuronext ParisISIN FR00040568512025DD1064406
5,274 shares@ €4.46847.3% of flowActionEuronext ParisISIN FR00040568512025DD1064410
9,588 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1063578
9,588 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1063582
22,424 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1063387
6,239 shares0ActionHors plateforme de négociationISIN FR00040568512025DD1063142
20,000 shares@ €2.5404100.0% of flowActionEuronext ParisISIN FR00040568512025DD1047895
Canonical exit: 8 Oct 2025 (T+90)
10,000 shares@ €2.430636.3% of flowActionEuronext ParisISIN FR00040568512025DD1045005
Canonical exit: 25 Sept 2025 (T+90)
27,521 shares0ActionHors plateforme de négociationISIN FR00040568512024DD1010179
14,844 shares0ActionHors plateforme de négociationISIN FR00040568512024DD1007273
19,176 shares0ActionHors plateforme de négociationISIN FR00040568512024DD1007280
25 of 78 declarations
About Valneva SE
Valneva SE is a European specialty biopharmaceutical company focused on prophylactic vaccines designed to prevent infectious diseases with unmet medical needs. The group is listed on Euronext Paris and Nasdaq under the ticker VALN and was created in 2013 through the merger of two biotechnology companies: Austria-based Intercell and France-based Vivalis. Its operational headquarters are in Saint-Herblain, France, and the company maintains an international footprint across Europe and North America, with activities in France, Austria, the United Kingdom, Sweden, Canada and the United States. Over time, Valneva has established itself as a niche player with expertise in travel and specialty vaccines.
The company’s core business spans vaccine research, development, manufacturing and commercialization. Its commercial portfolio includes three proprietary vaccines: IXIARO, for Japanese encephalitis; DUKORAL, for cholera and, in some countries, ETEC-related diarrhea; and IXCHIQ, the world’s first approved chikungunya vaccine. Valneva also commercializes certain third-party vaccines through its established distribution infrastructure, supporting its recurring revenue base. The company emphasizes a highly specialized strategy, targeting first-in-class, best-in-class, or only-in-class solutions in disease areas with meaningful regulatory and scientific barriers.
Read moreShow less
From a competitive standpoint, Valneva occupies a distinctive position. It is not a broad-based vaccine giant, but rather a focused specialist in travel vaccines and emerging infectious diseases. IXIARO has a long commercial track record, including a key U.S. supply relationship with the Department of Defense, which renewed a contract worth at least $32.8 million in January 2025. IXCHIQ is now a strategic growth asset: approved in the U.S. in late 2023, in Canada in 2024, and in the European Union in 2024 with an adolescent label expansion in 2025, it is positioned as a response to an important global unmet need. In parallel, the company continues to advance VLA15, its Lyme disease vaccine candidate developed with Pfizer and presented as the only active vaccine program in advanced clinical development for Lyme disease.
Recent highlights include the regulatory and geographic expansion of IXCHIQ and ongoing progress in the Lyme franchise. Valneva regularly reports results and guidance, underscoring a strategy centered on growing commercial vaccine sales to fund its pipeline. The company nonetheless remains a high-R&D-intensity biotech, with value creation heavily dependent on the clinical, regulatory and commercial performance of a small number of key assets.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
